ESBATech AG

16 articles about ESBATech AG

• OctoPlus Expands Development Agreement With ESBATech on Controlled Release Product for Ophthalmic Indications

  2/24/2011

• Alcon Laboratories, Inc. to Acquire Swiss Biotechnology Firm, ESBATech for $589 Million

  9/14/2009

• ESBATech: Topical ESBA105 Demonstrates Efficacy in the Back of the Eye to Inhibit Neovascularization

  3/24/2009

• ESBATech's Antibody Fragment ESBA105 Enters Phase IIa in Uveitis Study

  2/24/2009

• ESBATech's Antibody Fragment Enters Phase Ib/IIa in Ophthalmology

  2/3/2009

• ESBATech's Antibody Fragment Enters Phase I/IIa Clinical Development in Osteoarthritis with the Potential for Disease-Modifying Activity

  1/9/2009

• ESBATech Announces Successful Completion of Phase I Clinical Study for Lead Antibody Fragment in Ophthalmic Indications Preclinical Pharmacokinetic Data to be Presented at the 7th International Symposium on Uveitis in Germany

  9/8/2008

• ESBATech Raises Additional $22M, Extending Series B Venture Financing Positive Results to Date Drive Decision to Expand its Proprietary Therapeutic Pipeline

  8/7/2008

• ESBATech's Lead Antibody Fragment Enters Clinical Development for Ophthalmic Indications

  4/24/2008

• ESBATech's Antibody Fragments Demonstrate Penetration into the Eye with Topical Delivery via Eye Drops

  2/25/2008

• ESBATech Announces Appointment Of Martin Gertsch As Chief Financial Officer

  2/13/2007

• ESBATech Announces Spin-Out Of Kinase Inhibitor Programs To Form Oncalis AG

  9/6/2006

• ESBATech Closes $ 41M Series B Venture Financing

  8/2/2006

• ESBATech Announces Appointment Of James Egan As Chief Business Officer

  5/15/2006

• ESBATech To Present At The Rodman & Renshaw 3rd Annual Global Healthcare Conference

  5/8/2006

• ESBATech CEO To Present At Sachs Associates - Bloomberg L.P. 5th Annual North American Forum

  3/9/2006